The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company." ...

Skyhawk Therapeutics, a Boston-based biotechnology company, has unveiled final results from a small study testing a once-daily, “RNA splicing” pill as a treatment for Huntington’s disease.

First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers ...

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk ...

A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral ...

Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course ...

Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...

The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key ...

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings ...

Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in ...